{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:41:22Z","timestamp":1790523682293,"version":"4.1.0"},"reference-count":108,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T00:00:00Z","timestamp":1586736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cancers represent highly significant health issues and the options for their treatment are often not efficient to cure the disease. Immunotherapy strategies have been developed to modulate the patient\u2019s immune system in order to eradicate cancerous cells. For instance, passive immunization consists in the administration at high doses of exogenously produced monoclonal antibodies directed either against tumor antigen or against immune checkpoint inhibitors. Its main advantage is that it provides immediate immunity, though during a relatively short period, which consequently requires frequent injections. To circumvent this limitation, several approaches, reviewed here, have emerged to induce in vivo antibody secretion at physiological doses. Gene delivery vectors, such as adenoviral vectors or adeno-associated vectors, have been designed to induce antibody secretion in vivo after in situ cell modification, and have driven significant improvements in several cancer models. However, anti-idiotypic antibodies and escape mutants have been detected, probably because of both the continuous expression of antibodies and their expression by unspecialized cell types. To overcome these hurdles, adoptive transfer of genetically modified B cells that secrete antibodies either constitutively or in a regulated manner have been developed by ex vivo transgene insertion with viral vectors. Recently, with the emergence of gene editing technologies, the endogenous B cell receptor loci of B cells have been modified with the clustered regularly interspaced short palindromic repeats (CRISPR)\/CRISPR-associated endonuclease (Cas-9) system to change their specificity in order to target a given antigen. The expression of the modified BCR gene hence follows the endogenous regulation mechanisms, which may prevent or at least reduce side effects. Although these approaches seem promising for cancer treatments, major questions, such as the persistence and the re-activation potential of these engineered cells, remain to be addressed in clinically relevant animal models before translation to humans.<\/jats:p>","DOI":"10.3390\/cancers12040962","type":"journal-article","created":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T03:10:01Z","timestamp":1586833801000},"page":"962","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Towards Physiologically and Tightly Regulated Vectored Antibody Therapies"],"prefix":"10.3390","volume":"12","author":[{"given":"Audrey","family":"Page","sequence":"first","affiliation":[{"name":"CIRICentre International de Recherche en Infectiologie, Univ Lyon, Universit\u00e9 Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, 46 all\u00e9e d\u2019Italie, F-69007 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriane","family":"Fusil","sequence":"additional","affiliation":[{"name":"CIRICentre International de Recherche en Infectiologie, Univ Lyon, Universit\u00e9 Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, 46 all\u00e9e d\u2019Italie, F-69007 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8842-3726","authenticated-orcid":false,"given":"Fran\u00e7ois-Lo\u00efc","family":"Cosset","sequence":"additional","affiliation":[{"name":"CIRICentre International de Recherche en Infectiologie, Univ Lyon, Universit\u00e9 Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, 46 all\u00e9e d\u2019Italie, F-69007 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00000658-189112000-00015","article-title":"Contribution to the knowledge on Sarcoma","volume":"14","author":"Coley","year":"1891","journal-title":"Ann. Surg."},{"key":"ref_2","first-page":"3","article-title":"The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases","volume":"1991","author":"Coley","year":"1893","journal-title":"Clin. Orthop."},{"key":"ref_3","unstructured":"Fehleisen, F. (1883). Die Aetiologie des Erysipels, Theodor Fisch."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"79.23","DOI":"10.4049\/jimmunol.198.Supp.79.23","article-title":"New strategies in vaccine design for the induction of CD8 T cell responses using biodegradable iron oxide nanoparticles","volume":"198","author":"Powles","year":"2017","journal-title":"J. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Siegrist, C.-A. (2013). Vaccine immunology. Vaccines, Elsevier.","DOI":"10.1016\/B978-1-4557-0090-5.00004-5"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2015.08.021","article-title":"Rationale for anti-OX40 cancer immunotherapy","volume":"52","author":"Aspeslagh","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Marhelava, K., Pilch, Z., Bajor, M., Graczyk-Jarzynka, A., and Zagozdzon, R. (2019). Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer. Cancers, 11.","DOI":"10.3390\/cancers11111756"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: Recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/leu.2014.185","article-title":"Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice","volume":"29","author":"Macor","year":"2015","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3892\/mmr.2016.5292","article-title":"Construction and functional analysis of an anti-human cervical carcinoma\/anti-human CD3 single-chain bispecific antibody","volume":"14","author":"Wu","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Wu, L., Seung, E., Xu, L., Rao, E., Lord, D.M., Wei, R.R., Cortez-Retamozo, V., Ospina, B., Posternak, V., and Ulinski, G. (2019). Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. Nat. Cancer.","DOI":"10.1038\/s43018-019-0004-z"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/978-1-4939-8648-4_20","article-title":"Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity","volume":"Volume 1827","author":"Nevoltris","year":"2018","journal-title":"Antibody Engineering"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3389\/fimmu.2019.01296","article-title":"Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life","volume":"10","author":"Saunders","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_16","first-page":"1","article-title":"Adverse Events of Monoclonal Antibodies Used for Cancer Therapy","volume":"2015","author":"Guan","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kumar, V., Chaudhary, N., Garg, M., Floudas, C.S., Soni, P., and Chandra, A.B. (2017). Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00049"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8769","DOI":"10.1128\/JVI.76.17.8769-8775.2002","article-title":"Generation of Neutralizing Activity against Human Immunodeficiency Virus Type 1 in Serum by Antibody Gene Transfer","volume":"76","author":"Lewis","year":"2002","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/imr.12478","article-title":"Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention","volume":"275","author":"Brady","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Fuchs, S.P., Martinez-Navio, J.M., Piatak, M., Lifson, J.D., Gao, G., and Desrosiers, R.C. (2015). AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity. PLOS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005090"},{"key":"ref_21","first-page":"ra129","article-title":"Broadly neutralizing antibodies abrogate established hepatitis C virus infection","volume":"6","author":"Dorner","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1479-0556-2-13","article-title":"Skipping the co-expression problem: The new 2A \u201cCHYSEL\u201d technology","volume":"2","year":"2004","journal-title":"Genet. Vaccines Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11441","DOI":"10.1074\/jbc.M211644200","article-title":"Co-translational, Intraribosomal Cleavage of Polypeptides by the Foot-and-mouth Disease Virus 2A Peptide","volume":"278","author":"Hughes","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1517\/14712598.5.5.627","article-title":"Development of 2A peptide-based strategies in the design of multicistronic vectors","volume":"5","author":"Szymczak","year":"2005","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1042\/BST0360712","article-title":"Dissection of a co-translational nascent chain separation event","volume":"36","author":"Doronina","year":"2008","journal-title":"Biochem. Soc. Trans."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1128\/MCB.00421-08","article-title":"Site-Specific Release of Nascent Chains from Ribosomes at a Sense Codon","volume":"28","author":"Doronina","year":"2008","journal-title":"Mol. Cell. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1261\/rna.487907","article-title":"A case for \u201cStopGo\u201d: Reprogramming translation to augment codon meaning of GGN by promoting unconventional termination (Stop) after addition of glycine and then allowing continued translation (Go)","volume":"13","author":"Atkins","year":"2007","journal-title":"RNA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2014.07.105","article-title":"AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer","volume":"135","author":"Xie","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jconrel.2018.10.017","article-title":"Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases","volume":"291","author":"Sherbo","year":"2018","journal-title":"J. Controlled Release"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1158\/0008-5472.CAN-18-0363","article-title":"Intrathecal Viral Vector Delivery of Trastuzumab Prevents or Inhibits Tumor Growth of Human HER2-Positive Xenografts in Mice","volume":"78","author":"Rothwell","year":"2018","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.ymthe.2019.09.016","article-title":"Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses","volume":"27","author":"Martisova","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.celrep.2017.12.025","article-title":"A Recombinant Antibody-Expressing Influenza Virus Delays Tumor Growth in a Mouse Model","volume":"22","author":"Hamilton","year":"2018","journal-title":"Cell Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/cas.13228","article-title":"Recent advances in genetic modification of adenovirus vectors for cancer treatment","volume":"108","author":"Yamamoto","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.coph.2015.08.003","article-title":"Surface engineering of lentiviral vectors for gene transfer into gene therapy target cells","volume":"24","author":"Verhoeyen","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Basner-Tschakarjan, E., and Mingozzi, F. (2014). Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00350"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7598","DOI":"10.1016\/j.biomaterials.2014.05.032","article-title":"Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo","volume":"35","author":"Fitzpatrick","year":"2014","journal-title":"Biomaterials"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1016\/S1525-0016(16)43723-8","article-title":"PEGylation of VSV-G Pseudotyped Lentiviral Vectors Prevents Inactivation by Complement","volume":"5","author":"Croyle","year":"2002","journal-title":"Mol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Yao, T., Zhou, X., Zhang, C., Yu, X., Tian, Z., Zhang, L., and Zhou, D. (2017). Site-Specific PEGylated Adeno-Associated Viruses with Increased Serum Stability and Reduced Immunogenicity. Molecules, 22.","DOI":"10.3390\/molecules22071155"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00262-017-2042-7","article-title":"Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody","volume":"66","author":"Muthumani","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"28262","DOI":"10.18632\/oncotarget.8596","article-title":"Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab","volume":"7","author":"Xing","year":"2016","journal-title":"Oncotarget"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Liu, F.-R., Bai, S., Feng, Q., Pan, X.-Y., Song, S.-L., Fang, H., Cui, J., and Yang, J.-L. (2018). Anti-colorectal cancer effects of anti-p21Ras scFv delivered by the recombinant adenovirus KGHV500 and cytokine-induced killer cells. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4989-y"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00432-013-1417-1","article-title":"A recombinant adenovirus vector encoding the light chain of human coagulation factor VII and IgG1 Fc fragment to targeting tissue factor for colorectal cancer immunotherapy in the mouse model","volume":"139","author":"Rao","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1158\/1535-7163.MCT-15-0819","article-title":"Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive","volume":"15","author":"Liikanen","year":"2016","journal-title":"Cancer Mol. Cancer Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/gt.2015.71","article-title":"Recombinant AAV-mediated in vivo long-term expression and antitumour activity of an anti-ganglioside GM3(Neu5Gc) antibody","volume":"22","author":"Piperno","year":"2015","journal-title":"Gene Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/mt.2011.197","article-title":"2A Peptide-based, Lentivirus-mediated Anti-death Receptor 5 Chimeric Antibody Expression Prevents Tumor Growth in Nude Mice","volume":"20","author":"Li","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9176","DOI":"10.1158\/0008-5472.CAN-08-1688","article-title":"\u201cActive\u201d Cancer Immunotherapy by Anti-Met Antibody Gene Transfer","volume":"68","author":"Vigna","year":"2008","journal-title":"Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.18632\/oncotarget.26785","article-title":"PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models","volume":"10","author":"Mitchell","year":"2019","journal-title":"Oncotarget"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Vijayakumar, G., McCroskery, S., and Palese, P. (2019). Engineering Newcastle disease virus as oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines. J. Virol.","DOI":"10.1128\/JVI.01677-19"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Reul, J., Frisch, J., Engeland, C.E., Thalheimer, F.B., Hartmann, J., Ungerechts, G., and Buchholz, C.J. (2019). Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00052"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/gt.2011.176","article-title":"Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4","volume":"19","author":"Dias","year":"2012","journal-title":"Gene Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/mt.2014.160","article-title":"CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy","volume":"22","author":"Engeland","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1089\/hum.2007.109","article-title":"Gene Delivery of the Murine Equivalent of Bevacizumab (Avastin), an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody, to Suppress Growth of Human Tumors in Immunodeficient Mice. Hum","volume":"19","author":"Watanabe","year":"2008","journal-title":"Gene Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/mt.2015.191","article-title":"Host Anti-antibody Responses Following Adeno-associated Virus\u2013mediated Delivery of Antibodies Against HIV and SIV in Rhesus Monkeys","volume":"24","author":"Fuchs","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","article-title":"Immune Escape Mechanisms as a Guide for Cancer Immunotherapy","volume":"21","author":"Beatty","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.omtm.2019.11.010","article-title":"Liver-Directed but Not Muscle-Directed AAV-Antibody Gene Transfer Limits Humoral Immune Responses in Rhesus Monkeys","volume":"16","author":"Fuchs","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/sj.gt.3300632","article-title":"Systemic long-term delivery of antibodies in immunocompetent animals using cellulose sulphate capsules containing antibody-producing cells","volume":"5","author":"Pelegrin","year":"1998","journal-title":"Gene Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1089\/hum.1997.8.10-1219","article-title":"In Vitro and In Vivo Secretion of Cloned Antibodies by Genetically Modified Myogenic Cells","volume":"8","author":"Pelegrin","year":"1997","journal-title":"Hum. Gene Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1073\/pnas.80.20.6351","article-title":"Functional immunoglobulin M production after transfection of cloned immunoglobulin heavy and light chain genes into lymphoid cells","volume":"80","author":"Ochi","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0925-4439(96)00066-X","article-title":"Cytomedical therapy for IgG1 plasmacytosis in human interleukin-6 transgenic mice using hybridoma cells microencapsulated in alginate-poly(l) lysine-alginate membrane","volume":"1360","author":"Okada","year":"1997","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1182\/blood-2009-05-220798","article-title":"Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors","volume":"114","author":"Frecha","year":"2009","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1182\/blood-2014-02-558163","article-title":"Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs","volume":"124","author":"Amirache","year":"2014","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Tittlbach, H., Schneider, A., Strobel, J., Zimmermann, R., Maas, S., Gebhardt, B., Rauser, G., Mach, M., Mackensen, A., and Winkler, T.H. (2017). GMP-production of purified human B lymphocytes for the adoptive transfer in patients after allogeneic hematopoietic stem cell transplantation. J. Transl. Med., 15.","DOI":"10.1186\/s12967-017-1330-5"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1182\/blood-2008-09-177139","article-title":"Engineering human hematopoietic stem\/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes","volume":"113","author":"Luo","year":"2009","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/sj.gt.3303021","article-title":"Cell-specific and efficient expression in mouse and human B cells by a novel hybrid immunoglobulin promoter in a lentiviral vector","volume":"14","author":"Laurie","year":"2007","journal-title":"Gene Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/gt.2008.33","article-title":"Repopulation of B-lymphocytes with restricted gene expression using haematopoietic stem cells engineered with lentiviral vectors","volume":"15","author":"Taher","year":"2008","journal-title":"Gene Ther."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Freitag, J., Heink, S., Roth, E., Wittmann, J., J\u00e4ck, H.-M., and Kamradt, T. (2014). Towards the Generation of B-Cell Receptor Retrogenic Mice. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0109199"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Moutai, T., Yamana, H., Nojima, T., and Kitamura, D. (2014). A Novel and Effective Cancer Immunotherapy Mouse Model Using Antigen-Specific B Cells Selected In Vitro. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0092732"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12943-019-1092-1","article-title":"Recent updates on CAR T clinical trials for multiple myeloma","volume":"18","author":"Lin","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Suarez, E.R., Chang, D.-K., Sun, J., Sui, J., Freeman, G.J., Signoretti, S., Zhu, Q., and Marasco, W.A. (2016). Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget, 7.","DOI":"10.18632\/oncotarget.9114"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6982","DOI":"10.1158\/1078-0432.CCR-17-0867","article-title":"Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor\u2013Modified T Cells Engineered to Secrete Checkpoint Inhibitors","volume":"23","author":"Li","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_71","first-page":"92","article-title":"Immunoglobulin heavy chain gene regulation through polyadenylation and splicing competition: Immunoglobulin heavy chain gene regulation. Wiley Interdiscip","volume":"2","author":"Peterson","year":"2011","journal-title":"Rev. RNA"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Yu, K.K., Aguilar, K., Tsai, J., Galimidi, R., Gnanapragasam, P., Yang, L., and Baltimore, D. (2012). Use of Mutated Self-Cleaving 2A Peptides as a Molecular Rheostat to Direct Simultaneous Formation of Membrane and Secreted Anti-HIV Immunoglobulins. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0050438"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1099\/0022-1317-82-5-1027","article-title":"The \u2018cleavage\u2019 activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring \u20182A-like\u2019 sequences","volume":"82","author":"Donnelly","year":"2001","journal-title":"J. Gen. Virol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/sj.mt.6300142","article-title":"An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo","volume":"15","author":"Fang","year":"2007","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1038\/mt.2015.148","article-title":"A Lentiviral Vector Allowing Physiologically Regulated Membrane-anchored and Secreted Antibody Expression Depending on B-cell Maturation Status","volume":"23","author":"Fusil","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"8883","DOI":"10.1073\/pnas.83.23.8883","article-title":"Regulated production of mu m and mu s mRNA requires linkage of the poly(A) addition sites and is dependent on the length of the mu s-mu m intron","volume":"83","author":"Peterson","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1101\/gad.1.5.471","article-title":"Relative position and strengths of poly(A) sites as well as transcription termination are critical to membrane versus secreted mu-chain expression during B-cell development","volume":"1","author":"Galli","year":"1987","journal-title":"Genes Amp Dev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1128\/MCB.22.15.5606-5615.2002","article-title":"An RNA Polymerase Pause Site Is Associated with the Immunoglobulin s Poly(A) Site","volume":"22","author":"Peterson","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1089\/hum.2016.107","article-title":"Gene Editing of Human Hematopoietic Stem and Progenitor Cells: Promise and Potential Hurdles","volume":"27","author":"Yu","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Ott de Bruin, L.M., Volpi, S., and Musunuru, K. (2015). Novel Genome-Editing Tools to Model and Correct Primary Immunodeficiencies. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00250"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nm.3793","article-title":"Therapeutic genome editing: Prospects and challenges","volume":"21","author":"Cox","year":"2015","journal-title":"Nat. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1126\/science.272.5268.1649","article-title":"A Quasi-Monoclonal Mouse","volume":"272","author":"Cascalho","year":"1996","journal-title":"Science"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/334676a0","article-title":"Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice","volume":"334","author":"Goodnow","year":"1988","journal-title":"Nature"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Johnson, M.J., Laoharawee, K., Lahr, W.S., Webber, B.R., and Moriarity, B.S. (2018). Engineering of Primary Human B cells with CRISPR\/Cas9 Targeted Nuclease. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-30358-0"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"eaax0644","DOI":"10.1126\/sciimmunol.aax0644","article-title":"B cells engineered to express pathogen-specific antibodies protect against infection","volume":"4","author":"Moffett","year":"2019","journal-title":"Sci. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.isci.2019.01.032","article-title":"CRISPR-Mediated Editing of the B Cell Receptor in Primary Human B Cells","volume":"12","author":"Greiner","year":"2019","journal-title":"iScience"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Voss, J.E., Gonzalez-Martin, A., Andrabi, R., Fuller, R.P., Murrell, B., McCoy, L.E., Porter, K., Huang, D., Li, W., and Sok, D. (2019). Reprogramming the antigen specificity of B cells using genome-editing technologies. eLife, 8.","DOI":"10.7554\/eLife.42995"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Cheong, T.-C., Compagno, M., and Chiarle, R. (2016). Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system. Nat. Commun., 7.","DOI":"10.1038\/ncomms10934"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Lin, Y., Pecetta, S., Steichen, J.M., Kratochvil, S., Melzi, E., Arnold, J., Dougan, S.K., Wu, L., Kirsch, K.H., and Nair, U. (2018). One-step CRISPR\/Cas9 method for the rapid generation of human antibody heavy chain knock-in mice. EMBO J., 37.","DOI":"10.15252\/embj.201899243"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/aps.2017.2","article-title":"Therapeutic gene editing: Delivery and regulatory perspectives","volume":"38","author":"Shim","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41467-018-07845-z","article-title":"Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins","volume":"10","author":"Mangeot","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3389\/fgene.2018.00691","article-title":"Methodologies for Improving HDR Efficiency","volume":"9","author":"Liu","year":"2019","journal-title":"Front. Genet."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2006-05-023069","article-title":"Facilitating matched pairing and expression of TCR chains introduced into human T cells","volume":"109","author":"Kuball","year":"2007","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Brendel, C., Rio, P., and Verhoeyen, E. (2019). Humanized mice are precious tools for evaluation of hematopoietic gene therapies and preclinical modeling to move towards a clinical trial. Biochem. Pharmacol., 113711.","DOI":"10.1016\/j.bcp.2019.113711"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.stem.2019.02.019","article-title":"Precise Gene Editing Preserves Hematopoietic Stem Cell Function following Transient p53-Mediated DNA Damage Response","volume":"24","author":"Schiroli","year":"2019","journal-title":"Cell Stem Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","article-title":"CRISPR\u2013Cas9 genome editing induces a p53-mediated DNA damage response","volume":"24","author":"Haapaniemi","year":"2018","journal-title":"Nat. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/sctm.17-0244","article-title":"Factors Influencing the Umbilical Cord Blood Stem Cell Industry: An Evolving Treatment Landscape","volume":"7","author":"Dessels","year":"2018","journal-title":"Stem Cells Transl. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4103\/ajts.AJTS_124_18","article-title":"Umbilical cord blood quality and quantity: Collection up to transplantation","volume":"13","author":"Mousavi","year":"2019","journal-title":"Asian J. Transfus. Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.3389\/fimmu.2019.02630","article-title":"Molecular Design, Optimization, and Genomic Integration of Chimeric B Cell Receptors in Murine B Cells","volume":"10","author":"Pesch","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/jgm.2754","article-title":"Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter: New dual targeted gene therapies","volume":"16","author":"Leoh","year":"2014","journal-title":"J. Gene Med."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Uusi-Kerttula, H., Davies, J., Coughlan, L., Hulin-Curtis, S., Jones, R., Hanna, L., Chester, J.D., and Parker, A.L. (2016). Pseudotyped avb6 integrin-targeted adenovirus vectors for ovarian cancer therapies. Oncotarget, 7.","DOI":"10.18632\/oncotarget.8545"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s12033-016-9973-7","article-title":"Sindbis Virus-Pseudotyped Lentiviral Vectors Carrying VEGFR2-Specific Nanobody for Potential Transductional Targeting of Tumor Vasculature","volume":"58","author":"Ahani","year":"2016","journal-title":"Mol. Biotechnol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1089\/hum.1998.9.15-2165","article-title":"Genetically Engineered Antibodies in Gene Transfer and Gene Therapy","volume":"9","author":"Pelegrin","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Kasaraneni, N., Chamoun-Emanuelli, A.M., Wright, G., and Chen, Z. (2017). Retargeting Lentiviruses via SpyCatcher-SpyTag Chemistry for Gene Delivery into Specific Cell Types. mBio, 8.","DOI":"10.1128\/mBio.01860-17"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1182\/blood-2004-12-4736","article-title":"Novel lentiviral vectors displaying \u201cearly-acting cytokines\u201d selectively promote survival and transduction of NOD\/SCID repopulating human hematopoietic stem cells","volume":"106","author":"Verhoeyen","year":"2005","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1089\/10430349950017860","article-title":"Retroviral Display of Functional Binding Domains Fused to the Amino Terminus of Influenza Hemagglutinin","volume":"10","author":"Hatziioannou","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"ref_107","first-page":"401","article-title":"Efficient gene delivery to quiescent interleukin-2 (IL-2)-dependent cells by murine leukemia virus-derived vectors harboring IL-2 chimeric envelope glycoproteins","volume":"94","author":"Maurice","year":"1999","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood-2001-11-0042","article-title":"Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates","volume":"100","author":"Sandrin","year":"2002","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/4\/962\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:21:07Z","timestamp":1760361667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/4\/962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,13]]},"references-count":108,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["cancers12040962"],"URL":"https:\/\/doi.org\/10.3390\/cancers12040962","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,13]]}}}